- Home
- AFJK vs KPTI Comparison
AFJK vs KPTI Comparison
Compare AFJK & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- KPTI
- Stock Information
- Founded
- AFJK 2023
- KPTI 2008
- Country
- AFJK United States
- KPTI United States
- Employees
- AFJK N/A
- KPTI N/A
- Industry
- AFJK
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- AFJK
- KPTI Health Care
- Exchange
- AFJK NYSE
- KPTI Nasdaq
- Market Cap
- AFJK 96.8M
- KPTI 90.7M
- IPO Year
- AFJK 2023
- KPTI 2013
- Fundamental
- Price
- AFJK $10.75
- KPTI $0.66
- Analyst Decision
- AFJK
- KPTI Strong Buy
- Analyst Count
- AFJK 0
- KPTI 4
- Target Price
- AFJK N/A
- KPTI $5.00
- AVG Volume (30 Days)
- AFJK 59.0K
- KPTI 1.0M
- Earning Date
- AFJK 01-01-0001
- KPTI 02-27-2025
- Dividend Yield
- AFJK N/A
- KPTI N/A
- EPS Growth
- AFJK N/A
- KPTI N/A
- EPS
- AFJK 0.29
- KPTI N/A
- Revenue
- AFJK N/A
- KPTI $148,442,000.00
- Revenue This Year
- AFJK N/A
- KPTI $6.67
- Revenue Next Year
- AFJK N/A
- KPTI $8.58
- P/E Ratio
- AFJK $36.60
- KPTI N/A
- Revenue Growth
- AFJK N/A
- KPTI 1.77
- 52 Week Low
- AFJK $10.80
- KPTI $0.58
- 52 Week High
- AFJK $10.85
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- KPTI 44.20
- Support Level
- AFJK N/A
- KPTI $0.61
- Resistance Level
- AFJK N/A
- KPTI $0.73
- Average True Range (ATR)
- AFJK 0.00
- KPTI 0.08
- MACD
- AFJK 0.00
- KPTI -0.00
- Stochastic Oscillator
- AFJK 0.00
- KPTI 26.13
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.